---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000058"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-05-14T11:53:38+00:00"
generated_at: "2026-05-14T11:55:37.869719+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M

## Summary
- Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.
- Net loss $71.6M ($0.27 loss per share); cash equivalents $229.4M, down from $300.7M at Dec 2025.
- Reaffirms FY2026 AUCATZYL net product revenue guidance $120-135M; expects continued positive gross margin.
- Cost reduction: ~13% workforce cut; annualized savings ~$15M starting 2027; restructuring charges ~$8M.
- Clinical pipeline on track: pediatric ALL data end-2027; lupus nephritis data 2028; progressive MS initial data end-2026.

## SEC filing metadata
- accession: 0001730463-26-000058
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-05-14T11:53:38+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/0001730463-26-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/autl-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000058
- JSON: https://secwatch.observer/filing/0001730463-26-000058.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000058.txt

## Key facts
- Earnings Releases
  Autolus Therapeutics plc reported first quarter ended March 31, 2026 results: revenue $26.2 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Revenue: $26.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/0001730463-26-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.